Added value of health-related quality of life measurement in cancer clinical trials: The experience of the NCIC CTG

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 2, 2010, Pages 119-128

  Au, Heather Jane ^a   Ringash, Jolie ^b   Brundage, Michael ^c   Palmer, Michael ^c   Richardson, Harriet ^c   Meyer, Ralph M ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Cancer; Clinical trials; Health related quality of life; HRQoL; Oncology; Patient reported outcomes; PRO; Quality of life

Indexed keywords

ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; LETROZOLE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLACEBO; PREDNISONE; TAMOXIFEN; TEMOZOLOMIDE;

BREAST CANCER; CANADA; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL DECISION MAKING; COLORECTAL CANCER; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NATIONAL HEALTH ORGANIZATION; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CANADA; CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HEALTH STATUS; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 77950963307     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.15     Document Type: Review

References (81)

1. Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(32), 5078-5081 (2007). (Pubitemid 350232286)
2. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J. Clin. Oncol. 25(32), 5082-5086 (2007).
3. Bruner DW. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model. J. Natl Cancer Inst. Monogr. 37, 12-15 (2007).
4. Buchanan DR, O'Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J. Clin. Oncol. 23(3), 591-598 (2005).
5. Sloan JA, Frost MH, Berzon R et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 14, 988-998 (2006). (Pubitemid 44451304)
6. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer 41(2), 280-287 (2005). (Pubitemid 40126961)
7. Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual. Life Res. 1(3), 211-218 (1992).
8. Moinpour CV, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? J. Natl Cancer Inst. Monogr. 37, 31-38 (2007).
9. Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st Century. Washington: National Academy Press (2001).
10. Oliver A, Greenberg CC. Measuring outcomes in oncology treatment: the importance of patient-centered outcomes. Surg. Clin. N. Am. 89(1), 17-25 (2009).
11. Avery KNL, Gurjal S, Blazeby JM. Patient-reported outcomes to evaluate surgery. Expert Rev. Pharmacoeconomics Outcomes Res. 8(1), 43-50 (2008).
12. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J. Clin. 57(5), 278-300 (2007). (Pubitemid 47628455)
13. Schwartz CE, Sprangers MAG. An introduction to quality of life assessment in oncology: the value of measuring patient-reported outcomes. Am. J. Manag. Care 8(18 Suppl.), S550-S559 (2002).
14. Krause NM, Jay GM. What do global self-rated health items measure? Medical Care 32(9), 930-942 (1994).
15. Warnecke RB, Ferrans CE, Johnson TP et al. Measuring quality of life in culturally diverse populations. J. Natl Cancer Inst. Mongr. 20, 29-38 (1996).
16. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision-making. Ann. Oncol. 18(4), 775-781 (2007). (Pubitemid 46523284)
17. Efficace F, Bottomley A, Osoba D et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision-making? J. Clin. Oncol. 21(18), 3502-3511 (2003). (Pubitemid 46594084)
18. Au HJ, Brundage M, Ringash J et al. Added value of health-related quality of life (QoL) outcomes in NCIC CTG clinical trials: results from QoL Committee Workshop. Qual. Life Res. Suppl. A-71 (2007).
19. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1(3), 277-299 (1975).
20. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996). (Pubitemid 26185452)
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365-376 (1993).
22. Osoba D, Tannock IF, Ernst D, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prenisone. J. Clin. Oncol. 17(6), 1654-1663 (1999). (Pubitemid 29269233)
23. Jonker DJ, O'Callaghan CJ, Karapetis CS. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
24. Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
25. Au HJ, Karapetis CS, O'Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J. Clin. Oncol. 27(11), 1822-1828 (2009).
26. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
27. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. J. Cancer 30A, 635-642 (1994). (Pubitemid 24164250)
28. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erolotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Clin. Oncol. 24(24), 3831-3837 (2006). (Pubitemid 46630729)
29. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
30. Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res. 5(1), 139-150 (1996). (Pubitemid 26100512)
31. Taphoorn MJB, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 6(12), 937-944 (2005). (Pubitemid 41685226)
32. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. Lancet 359(9325), 2235-2241 (2002). (Pubitemid 34717977)
33. Davis AM, O'Sullivan B, Bell RS et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J. Clin. Oncol. 20(22), 4472-4477 (2002). (Pubitemid 35334759)
34. Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual. Life Res. 5(5), 508-516 (1996). (Pubitemid 26382286)
35. Davis AM, O'Sullivan B, Turcotte R et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 75(1), 48-53 (2005). (Pubitemid 40616794)
36. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
37. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 107(2), 431-434 (2006). (Pubitemid 43076361)
38. Norris B, Pritchard K, James K et al. A Phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/ recurrent breast cancer (MBC): a National Cancer Institute of Canada (NCIC CTG) study. Proc. Am. Soc. Clin. Oncol. 15, 98a (1996) (Abstract 59).
39. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J. Clin. Oncol. 18(12), 2395-2405 (2000). (Pubitemid 30415826)
40. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005). (Pubitemid 41007845)
41. Bezjak A, Lee CW, Ding K et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J. Clin. Oncol. 26(31), 5052-5059 (2008).
42. Jang RW, Le Maître A, Ding K et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J. Clin. Oncol. 27(26), 4268-4273 (2009).
43. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793 - 1802 (2003). (Pubitemid 37362955)
44. Ware JE, Snow KK, Kosinksi M et al. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, MA, USA (1993).
45. Hilditch JR, Lewis J, Peter A et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24, 161-175 (1996). (Pubitemid 26241870)
46. Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol. 23(28), 6931-6940 (2005). (Pubitemid 46260279)
47. Savage C, Pater J, Tu D, Norris B. He said/ she said: how much agreement is there on symptoms between common toxicity criteria and quality of life? Proc. Am. Soc. Clin. Oncol. 21(Part 1), 386a (2002).
48. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin- cyclophosphamide in women with advanced ovarian cancer. J. Natl Cancer Inst. 92(9), 699-708 (2000).
49. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J. Clin. Oncol. 22(12), 2461-2468 (2004). (Pubitemid 41115405)
50. Duncan GG, Epstein JB, Tu D et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27(5), 421-428 (2005). (Pubitemid 40593897)
51. Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol. 108(1), 100-105 (2008). (Pubitemid 350299429)
52. Latreille J, Stewart D, Laberge F et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 3(5), 307-312 (1995).
53. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 12(5), 1050-1057 (1994).
54. Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual. Life Res. 6(2), 151-158 (1997). (Pubitemid 27207280)
55. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol. 26(8), 1355-1363 (2008).
56. Curran D, Giralt J,Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25(16), 2191-2197 (2007). (Pubitemid 46954642)
57. Quinten C, Coens C, Mauer M et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 10, 865-871 (2009).
58. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual. Life Outcomes 7, 102 (2009).
59. Coates AS, Hurny C, Peterson HF et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J. Clin. Oncol. 18(22), 3768-3885 (2004). (Pubitemid 32694548)
60. Efficace F, Therasse P, Piccart MJ et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J. Clin. Oncol. 22(16), 3381-3388 (2004). (Pubitemid 41103697)
61. Tross S, Herndon J 2nd, Korzun A et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer: Cancer and Leukemia Group B. J. Natl Cancer Inst. 88(10), 661-667 (1996). (Pubitemid 26152552)
62. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J. Clin. Oncol. 15(8), 2966-2973 (1997). (Pubitemid 27330025)
63. Pater J, Osoba D, Zee B. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual. Life Res. 7(3), 273-278 (1998). (Pubitemid 28180047)
64. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision-making. Eur. J. Cancer 44(11), 1497-1506 (2008).
65. Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med. Care 40(Suppl.), III-31-III- 38 (2002).
66. Osoba D. The clinical value and meaning of health-related quality of life outcomes in oncology. In: Outcomes Assessment in Cancer: Measures, Methods, and Applications. Lipscomb J, Gotay CC, Snyder D (Eds). Cambridge University Press, UK, 386-405 (2005).
67. Lipscomb J, Gotay CC, Snyder C. Introduction to outcomes assessment in cancer. In: Outcomes Assessment in Cancer: Measures, Methods, and Applications. Lipscomb J, Gotay CC, Snyder D (Eds). Cambridge University Press, UK, 1-14 (2005).
68. Shih YCT, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J. Clin. 58(4), 231-244 (2008).
69. Osoba D, Rodrigues, G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139-144 (1998). (Pubitemid 28041591)
70. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality-of-life assessment: patient compliance with questionnaire completion. J. Natl Cancer Inst. 84(13), 1023-1026 (1992).
71. Osoba D, Bezjak A, Brundage M, Pater J; National Cancer Institute of Canada Clinical Trials Group. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health 10(Suppl. 2), S138-S145 (2007). (Pubitemid 350098931)
72. Bush N, Donaldson G, Moinpour C et al. Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Qual. Life Res. 14, 77-93 (2005). (Pubitemid 40249083)
73. Fayers P. Applying item response theory and computer adaptive testing: the challenges for health outcomes assessment. Qual. Life Res. 16, 187-194 (2007). (Pubitemid 47036923)
74. Osoba D. Translating the science of patient-reported outcomes assessment into clinical practice. J. Natl Cancer Inst. Monogr. 37, 5-11 (2007).
75. Clauser SB, Ganz PA, Lipscomb J, Reeve BB. Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision-making. J. Clin. Oncol. 25(32), 5049-5050 (2007). (Pubitemid 350232282)
76. Cella D, Yount S, Rothrock N et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap Cooperative Group during its first two years. Medical Care 45(5), S3-S11 (2007).
77. Revicki DA, Sloan J. Practical and philosophical issues surrounding a national item bank: if we build it will they come? Qual. Life Res. 16, 167-174 (2007). (Pubitemid 47036926)
78. Arora NK. Importance of patient-centred care in enhancing patient well-being: a cancer survivor's perspective. Qual. Life Res. 18, 1-4 (2009).
79. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual. Life Res. 18, 115-123 (2009).
80. Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual. Life Res. 18, 99-107 (2009).
81. Mandrekar S, Dueck A. Future direction in QOL research. Curr. Probl. Cancer. 29(6), 343-351 (2005).